vs
Side-by-side financial comparison of Incyte (INCY) and OPEN TEXT CORP (OTEX). Click either name above to swap in a different company.
OPEN TEXT CORP is the larger business by last-quarter revenue ($1.3B vs $1.3B, roughly 1.0× Incyte). Incyte runs the higher net margin — 23.8% vs 13.5%, a 10.4% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 2.2%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs -3.0%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Open Text Corporation is a global software company that develops and sells information management software.
INCY vs OTEX — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | ||
|---|---|---|
| Revenue | $1.3B | $1.3B |
| Net Profit | $303.3M | $172.7M |
| Gross Margin | — | 73.1% |
| Operating Margin | 23.7% | 15.7% |
| Net Margin | 23.8% | 13.5% |
| Revenue YoY | 20.9% | 2.2% |
| Net Profit YoY | 91.7% | — |
| EPS (diluted) | $1.47 | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $1.3B | ||
| Q4 25 | $1.5B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $1.1B | $1.3B | ||
| Q2 24 | $1.0B | $1.4B |
| Q1 26 | $303.3M | $172.7M | ||
| Q4 25 | $299.3M | $168.1M | ||
| Q3 25 | $424.2M | $146.6M | ||
| Q2 25 | $405.0M | $28.8M | ||
| Q1 25 | $158.2M | $92.8M | ||
| Q4 24 | $201.2M | $229.9M | ||
| Q3 24 | $106.5M | $84.4M | ||
| Q2 24 | $-444.6M | $248.2M |
| Q1 26 | — | 73.1% | ||
| Q4 25 | 92.0% | 74.0% | ||
| Q3 25 | 92.8% | 72.8% | ||
| Q2 25 | 93.5% | 72.3% | ||
| Q1 25 | 93.0% | 71.6% | ||
| Q4 24 | 92.5% | 73.3% | ||
| Q3 24 | 92.4% | 71.7% | ||
| Q2 24 | 92.7% | 72.5% |
| Q1 26 | 23.7% | 15.7% | ||
| Q4 25 | 22.3% | 22.0% | ||
| Q3 25 | 32.5% | 21.0% | ||
| Q2 25 | 43.6% | 13.9% | ||
| Q1 25 | 19.5% | 16.7% | ||
| Q4 24 | 25.6% | 22.2% | ||
| Q3 24 | 12.8% | 16.3% | ||
| Q2 24 | -45.8% | 14.2% |
| Q1 26 | 23.8% | 13.5% | ||
| Q4 25 | 19.9% | 12.7% | ||
| Q3 25 | 31.1% | 11.4% | ||
| Q2 25 | 33.3% | 2.2% | ||
| Q1 25 | 15.0% | 7.4% | ||
| Q4 24 | 17.1% | 17.2% | ||
| Q3 24 | 9.4% | 6.6% | ||
| Q2 24 | -42.6% | 18.2% |
| Q1 26 | $1.47 | $0.70 | ||
| Q4 25 | $1.46 | $0.66 | ||
| Q3 25 | $2.11 | $0.58 | ||
| Q2 25 | $2.04 | $0.11 | ||
| Q1 25 | $0.80 | $0.35 | ||
| Q4 24 | $0.90 | $0.87 | ||
| Q3 24 | $0.54 | $0.32 | ||
| Q2 24 | $-2.04 | $0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.3B |
| Total DebtLower is stronger | — | $6.2B |
| Stockholders' EquityBook value | $5.6B | $4.0B |
| Total Assets | $7.3B | $13.3B |
| Debt / EquityLower = less leverage | — | 1.57× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $3.1B | $1.3B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.7B | $1.1B | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $987.3M | $1.3B |
| Q1 26 | — | $6.2B | ||
| Q4 25 | — | $6.4B | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.4B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.4B |
| Q1 26 | $5.6B | $4.0B | ||
| Q4 25 | $5.2B | $4.0B | ||
| Q3 25 | $4.7B | $4.0B | ||
| Q2 25 | $4.2B | $3.9B | ||
| Q1 25 | $3.7B | $4.1B | ||
| Q4 24 | $3.4B | $4.2B | ||
| Q3 24 | $3.2B | $4.1B | ||
| Q2 24 | $3.0B | $4.2B |
| Q1 26 | $7.3B | $13.3B | ||
| Q4 25 | $7.0B | $13.6B | ||
| Q3 25 | $6.3B | $13.5B | ||
| Q2 25 | $5.8B | $13.8B | ||
| Q1 25 | $5.7B | $13.8B | ||
| Q4 24 | $5.4B | $13.7B | ||
| Q3 24 | $5.0B | $13.8B | ||
| Q2 24 | $4.7B | $14.2B |
| Q1 26 | — | 1.57× | ||
| Q4 25 | — | 1.58× | ||
| Q3 25 | — | 1.61× | ||
| Q2 25 | — | 1.62× | ||
| Q1 25 | — | 1.55× | ||
| Q4 24 | — | 1.51× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | — | $354.6M |
| Free Cash FlowOCF − Capex | — | $305.0M |
| FCF MarginFCF / Revenue | — | 23.8% |
| Capex IntensityCapex / Revenue | — | 3.9% |
| Cash ConversionOCF / Net Profit | — | 2.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | $809.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $354.6M | ||
| Q4 25 | $543.3M | $318.7M | ||
| Q3 25 | $559.4M | $147.8M | ||
| Q2 25 | $44.7M | $158.2M | ||
| Q1 25 | $266.1M | $402.2M | ||
| Q4 24 | $381.2M | $348.0M | ||
| Q3 24 | $310.9M | $-77.8M | ||
| Q2 24 | $-575.6M | $185.2M |
| Q1 26 | — | $305.0M | ||
| Q4 25 | — | $279.4M | ||
| Q3 25 | — | $101.2M | ||
| Q2 25 | — | $124.0M | ||
| Q1 25 | — | $373.8M | ||
| Q4 24 | — | $306.7M | ||
| Q3 24 | — | $-117.1M | ||
| Q2 24 | — | $145.2M |
| Q1 26 | — | 23.8% | ||
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 9.5% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | -9.2% | ||
| Q2 24 | — | 10.7% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 2.9% |
| Q1 26 | — | 2.05× | ||
| Q4 25 | 1.82× | 1.90× | ||
| Q3 25 | 1.32× | 1.01× | ||
| Q2 25 | 0.11× | 5.49× | ||
| Q1 25 | 1.68× | 4.33× | ||
| Q4 24 | 1.89× | 1.51× | ||
| Q3 24 | 2.92× | -0.92× | ||
| Q2 24 | — | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INCY
Segment breakdown not available.
OTEX
| Customer support | $564.8M | 44% |
| Cloud services and subscriptions | $492.9M | 38% |
| License | $145.1M | 11% |
| Professional service and other | $79.6M | 6% |